PERSONALIZED MEDICINE

Each human being’s biology is different, as is the reaction of each individual to the same pharmacological treatment.

Despite this, treatment for these diseases is mainly standard, producing ineffective treatments and unnecessary side effects, which in the case of serious illnesses, such as cancer, may have severe consequences for the patient.

Vivia is developing a new Personalized Medicine test for hematologic cancers such as leukemia, lymphoma and multiple myeloma. This test is capable of predicting the best treatment for each patient prior to its administration. This is essential information we furnish to specialists, in order to help them make the best decision when deciding on the treatment for their patients.

This innovative test enjoys the collaboration of hematologists specializing in these diseases within the framework of the PETHEMA foundation. Aware of the need for having this kind of test and of the potential of the ExviTech Platform to turn personalized medicine for these diseases into a reality, Vivia and PETHEMA have reached a strategic alliance which boosts the commitment of both institutions to improve the treatment and quality of life of patients with hematologic cancers. Thus, Vivia’s goal is to work with the best specialists in order to ensure that the patient receives the best suited treatment–a personalized treatment. Initially, Vivia has focused on patients that do not respond favorably to the main treatments and, given that it is unclear which treatment could be effective, need an urgent alternative. In these cases, Vivia’s test is even more necessary, giving the patient vital hope and helping the specialist choose the effective treatment when s/he most needs said support.

Why is it important to personalize the treatment of Cancer?

Within the specific field of Hematologic Cancers, around 20-30% of patients with these diseases do not respond well to standard treatments administered as a first treatment option. This non-response percentage increases considerably, up to 50% or even more, in the case of patients who are resistant to the initial treatment or who suffer relapses after initial remission, which happens frequently.